Mutual of America Capital Management LLC cut its position in shares of Fortrea Holdings Inc. (NASDAQ:FTRE – Free Report) by 95.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,626 shares of the company’s stock after selling 236,936 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Fortrea were worth $57,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the business. Sequoia Financial Advisors LLC grew its position in shares of Fortrea by 1.0% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 176,159 shares of the company’s stock worth $870,000 after buying an additional 1,802 shares during the period. Verdence Capital Advisors LLC grew its position in shares of Fortrea by 12.8% during the 2nd quarter. Verdence Capital Advisors LLC now owns 16,046 shares of the company’s stock worth $79,000 after buying an additional 1,827 shares during the period. Quarry LP grew its holdings in Fortrea by 73.4% in the first quarter. Quarry LP now owns 7,567 shares of the company’s stock worth $57,000 after purchasing an additional 3,202 shares during the period. Brooklyn Investment Group grew its holdings in Fortrea by 9,577.5% in the first quarter. Brooklyn Investment Group now owns 3,871 shares of the company’s stock worth $29,000 after purchasing an additional 3,831 shares during the period. Finally, State of Alaska Department of Revenue grew its holdings in Fortrea by 8.5% in the second quarter. State of Alaska Department of Revenue now owns 53,909 shares of the company’s stock worth $266,000 after purchasing an additional 4,207 shares during the period.
Insider Activity at Fortrea
In other Fortrea news, Director Peter M. Neupert bought 32,500 shares of the firm’s stock in a transaction dated Monday, August 11th. The stock was purchased at an average cost of $6.26 per share, with a total value of $203,450.00. Following the transaction, the director directly owned 98,132 shares in the company, valued at $614,306.32. This trade represents a 49.52% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Erin L. Russell bought 9,854 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were acquired at an average cost of $10.15 per share, with a total value of $100,018.10. Following the completion of the transaction, the director owned 9,854 shares in the company, valued at approximately $100,018.10. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders acquired 72,354 shares of company stock valued at $507,168 and sold 10,311 shares valued at $94,635. 0.38% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Read Our Latest Report on FTRE
Fortrea Stock Performance
Shares of FTRE stock opened at $10.03 on Friday. The firm has a 50-day moving average of $9.87 and a 200-day moving average of $7.07. The company has a market cap of $910.72 million, a P/E ratio of -0.88, a P/E/G ratio of 0.46 and a beta of 1.81. The company has a debt-to-equity ratio of 1.87, a current ratio of 1.02 and a quick ratio of 1.02. Fortrea Holdings Inc. has a one year low of $3.97 and a one year high of $25.28.
Fortrea (NASDAQ:FTRE – Get Free Report) last posted its quarterly earnings data on Friday, May 24th. The company reported $0.37 EPS for the quarter. The firm had revenue of $693.90 million during the quarter. Fortrea had a negative net margin of 37.57% and a positive return on equity of 5.25%. Equities research analysts forecast that Fortrea Holdings Inc. will post 0.51 EPS for the current fiscal year.
Fortrea Company Profile
Fortrea Holdings Inc, a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Featured Stories
- Five stocks we like better than Fortrea
- Why Are These Companies Considered Blue Chips?
- Why Microsoft’s Post-Earnings Dip Is a Buy-the-Pause Moment
- Following Congress Stock Trades
- NVIDIA’s Billion-Dollar Bet Puts Nokia Back in the Growth Game
- What is diluted earnings per share (Diluted EPS)?
- Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations
Want to see what other hedge funds are holding FTRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fortrea Holdings Inc. (NASDAQ:FTRE – Free Report).
Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.
